JPRN-UMIN000025126招募中未知
A biomarker analysis of Afatinib treatment in patients with relapse of EGFR-T790M mutation-positive advanced lung adenocarcinoma after 3rd generation EGFR-TKI treatment. - A biomarker analysis of Afatinib treatment in patients with relapse of EGFR-T790M mutation-positive advanced lung adenocarcinoma after 3rd generation EGFR-TKI treatment.
Kurume University School of Medicine0 个研究点目标入组 30 人开始时间: 2016年12月3日最近更新:
适应症
试验速览
- 阶段
- 未知
- 状态
- 招募中
- 发起方
- 入组人数
- 30
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 20years-old 至 ot applicable（—）
- 性别
- All
入选标准
- 未提供
排除标准
- •1) Active double cancer (simultaneous double cancer/multiple cancer, and metachronous double cancer/multiple cancer within 5 years of disease-free period. However, carcinoma in situ and a lesion equivalent to intramucosal carcinoma judged cured by local therapy are not included as active double cancer/multiple cancer). 2) Evidence of interstitial pneumonia or pulmonary fibrosis by chest CT scan. 3) Symptomatic brain metastasis (clinically stable brain metastasis is eligible) 4) HBs antigen-positive 5) Infection requiring systemic treatment 6) Patients who, in the opinion of the attending physician, are inappropriate for the study
研究者
相似试验
已完成
不适用
Biomarker study for afatinib plus bevacizimabon-small cell lung cancer with EGFR mutationsJPRN-UMIN000032489Okayama University100
已完成
不适用
Study of association between effect of afatinib for EGFR-mutated non-small cell lung cancer and circulating free DNA detected with high sensitive analyses for EGFR mutation.non-small cell lung cancerJPRN-UMIN000014091Makoto Maemondo30
招募中
2 期
The Clinical Trial of BIBW2992 for patients with solid tumors harboring NRG1 fusioPatients with solid cancer harboring NRG1 fusion geneneoplasmsD009369JPRN-jRCT2041220036Ando Yuichi30
进行中（未招募）
2 期
EJ025Bon-sequamous non-small cell lung cancerJPRN-jRCTs021200005Maemondo Makoto35
进行中（未招募）
3 期
ACHILLES study/TORG1834Advanced non-small cell lung cancerJPRN-jRCTs031180175TANAKA Hiroshi106